Alnylam Pharmaceuticals, Inc. (ALNY) Financials

ALNY Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 3.8 billion 4.1 billion
2023-09-30 3.8 billion 4.0 billion
2023-06-30 3.4 billion 3.8 billion
2023-03-31 3.4 billion 3.7 billion

ALNY Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -45.1 million 42.0 million
2023-09-30 342.3 million 63.9 million
2023-06-30 -74.9 million 75.8 million
2023-03-31 -180.4 million 39.9 million

ALNY Net Income

No data available :(

ALNY Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 2.4 billion - 284.6 million
2023-09-30 2.4 billion - 289.2 million
2023-06-30 2.1 billion 1.0 billion 295.5 million
2023-03-31 2.1 billion 1.0 billion 302.5 million

ALNY Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 125.6 million
2023-09-30 131.3 million
2023-06-30 124.7 million
2023-03-31 124.1 million

ALNY Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 15.3 million 272.1 million 198.1 million -
2023-09-30 17.1 million 253.2 million 199.2 million -
2023-06-30 15.9 million 248.5 million 214.7 million -
2023-03-31 13.9 million 230.6 million 183.7 million -

ALNY Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 439.7 million 85.9 million
2023-09-30 750.5 million 84.3 million
2023-06-30 318.8 million 85.4 million
2023-03-31 319.3 million 54.9 million

ALNY

Price: $152.33

52 week price:
143.31
218.88

Earnings Per Share: -3.52 USD

P/E Ratio: -41.14

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 712302

Ebitda: -143.6 million

Market Capitalization: 19.2 billion

Links: